Clinical Pearls for Management of Acetaminophen Toxicity

Acetaminophen toxicity can occur due to acute ingestion or chronic excessive dosage. The progression of toxicity is categorized and patients' clinical presentation may vary depending on time from ingestion. Pharmacists will utilize the content of this presentation to recognize the state and make informed treatment decisions when confronted with a patient demonstrating acetaminophen toxicity. This session will emphasize the best practice methods and key points from primary literature on treating acetaminophen toxicity.

Learning Objectives

At the completion of this activity, the participant should be able to:

  • Explain the pharmacokinetics and pathophysiology of acetaminophen toxicity
  • Discuss the principles of treatment for acetaminophen toxicity
  • Describe key points published within current literature to support recommendations for antidote therapy
  • Construct a treatment plan for management of a patient presenting with an acute acetaminophen ingestion


Jennifer Hammond, PharmD, is a PGY2 Emergency Medicine Pharmacy Resident at Baystate Medical Center. She received her PharmD from the University of New England School of Pharmacy in 2021. Her professional interests include critical care and emergency medicine

Course Fee: Free for MCPHS alumni, full-time staff, and for all other professionals.

Release Date: June 15, 2023
Expiration Date: June 14, 2024
ACPE UAN: 0026-0000-23-013-H01-P | Knowledge
Topic Designator: Disease State Management/Drug Therapy
Contact Hours: 1.0 (0.1 CEU)

After registering or logging into, you can view CE modules in our library.

Accreditation Council for Pharmacy Education LogoMassachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MCPHS designates this educational activity for a total of 1.0 contact hours (0.1 CEUs).

To receive credit, participants must complete pre and post-assessments, view the entire presentation, and evaluate the session. Participant credit will be reported to the CPE Monitor upon conclusion. Transcripts may be printed from the CPE Monitor.

Massachusetts College of Pharmacy and Health Sciences adheres to the ACPE Standards for Integrity and Independence in Continuing Education. It is the policy of MCPHS that the speakers and planning committee members disclose all financial relationships with ineligible companies within the last 24 months, and that relevant conflicts of interest are mitigated. Speakers will disclose any off-label/unapproved use of drugs or devices during their presentation.

Jennifer Hammond, PharmD, has no relevant financial relationships with ineligible companies to disclose. She will discuss the off-label/investigational usage of fomepizole and intravenous acetylcysteine in the setting of acetaminophen toxicity.

Content Reviewer, Danyel Adams, PharmD, has no relevant financial relationships with ineligible companies to disclose.

Massachusetts College of Pharmacy and Health Sciences Continuing Education staff members hold no financial relationships with ineligible companies, related to the content of this presentation.

No funding from industry provided for this event. No exhibitors will be present.